



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00, 31/415, 31/18, 31/42	A2	(11) International Publication Number: WO 98/22101 (43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21489 (22) International Filing Date: 19 November 1997 (19.11.97) (30) Priority Data: 60/031,404 19 November 1996 (19.11.96) US (71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MASFERRER, Jaime, L. [CL/US]; 1213 Blairshire, Ballwin, MO 63011 (US). RAZ, Amiram [IL/IL]; Tarad Street 9, Ramat-Gan, 52503 Israel (IL). (74) Agent: BULOCK, Joseph, W.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS (57) Abstract <p>This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating angiogenic disorders.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

**METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS
AS ANTI-ANGIOGENIC AGENTS**

Field of the Invention

5
This invention is in the field of the prevention and treatment of angiogenesis. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and
10 treating angiogenesis-related disorders.

Background of the Invention

Prostaglandins play a major role in the
15 inflammation process and the inhibition of prostaglandin production, especially production of PGG₂, PGH₂ and PGE₂, has been a common target of anti-inflammatory drug discovery. However, common non-steroidal anti-inflammatory drugs (NSAID's) that are active in reducing
20 the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAID's can produce severe
25 side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAID's is the use of corticosteroids, which also produce severe adverse effects, especially when long term therapy is involved.

30 NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme
35 cyclooxygenase (COX). The recent discovery of an inducible enzyme associated with inflammation

(named "cyclooxygenase-2 (COX-2)" or "prostaglandin G/H synthase II") provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects.

Angiogenesis is the development of new blood vessels into a tissue or organ. Under normal conditions, angiogenesis is observed in wound healing and embryonal development. Uncontrolled angiogenesis is associated with neoplastic disease, tumor metastasis and other angiogenesis-related diseases.

Although originally developed for their anti-inflammatory properties, glucocorticoids are now recognized to have a wide variety of therapeutic uses. For example, many steroids with anti-inflammatory activity inhibit angiogenesis (U.S. Pat. No. 5,646,136).

20

Compounds which selectively inhibit cyclooxygenase-2 have been described in U.S. patents 5,380,738, 5,344,991, 5,393,790, 5,434,178, 5,474,995, 5,475,018, 5,510,368 and WO documents WO96/06840, WO95/21817, WO96/03388, WO96/03387, WO96/03392, WO96/25405, WO96/24584, WO96/03385, WO96/16934, WO95/15316, WO94/15932, WO94/27980, WO95/00501, WO94/13635, WO94/20480, and WO94/26731.

30

[Pyrazol-1-yl]benzenesulfonamides have been described as inhibitors of cyclooxygenase-2 and have shown promise in the treatment of inflammation, arthritis, and pain, with minimal side effects in pre-clinical and clinical trials. Their use for preventing colon cancer has been described in U.S. Patent No. 5,466,823. However, their use for treating or preventing

angiogenesis-related diseases has not been previously described.

There have been several publications describing the benefits of inhibiting angiogenesis. WO patent publication No. 96/19469 describes that COX-2 inhibitors would be useful to prevent and/or treat tumor angiogenesis and diabetic retinopathy.

The present invention is directed to the use of inhibitors of cyclooxygenase-2 for the treatment and prevention of tumor growth and metastasis that are dependent on the angiogenic process. In addition, the treatment and prevention of non-neoplastic angiogenesis-related disorders, such as retinopathies, and endometriosis is also included.

Detailed Description of the Invention

The present invention provides a method for treating or preventing angiogenesis-related disorders in a subject in need of such treatment or prevention, the method comprises treating the subject with a therapeutically effective amount of a cyclooxygenase-2 inhibitor or derivative or pharmaceutically-acceptable salt thereof.

The method above would be useful for, but not limited to, the treatment of angiogenesis-related disorders in a subject. According to the present invention, the compounds of Formula I are administered to a subject in need of angiogenesis inhibition. The method would be useful for treatment of neoplasia, including metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy,

retrolental fibroplasia and neovascular glaucoma;
ulcerative diseases such as gastric ulcer; pathological,
but non-malignant, conditions such as hemangiomas,
including invantile hemaginomas, angiofibroma of the
5 nasopharynx and avascular necrosis of bone; and
disorders of the female reproductive system such as
endometriosis.

The term "treatment" includes partial or total
10 inhibition of angiogenesis, including neoplastic growth,
spreading or metastasis, as well as partial or total
destruction of the neoplastic cells.

The term "prevention" includes either preventing
15 the onset of clinically evident angiogenesis altogether
or preventing the onset of a preclinically evident stage
of angiogenesis in individuals at risk. Also intended to
be encompassed by this definition is the prevention of
metastasis of malignant cells or to arrest or reverse
20 the progression of malignant cells. This includes
prophylactic treatment of those at risk of developing
angiogenesis.

The phrase "therapeutically-effective" is intended
25 to qualify the amount of each agent which will achieve
the goal of improvement in disease severity and the
frequency of incidence over treatment of each agent by
itself, while avoiding adverse side effects typically
associated with alternative therapies.

30

The term "subject" for purposes of treatment
includes any human or animal subject who has any
one of the known angiogenesis-related disorders.
For methods of prevention, the subject is any human
35 or animal subject, and preferably is a human
subject who is at risk for obtaining an
angiogenesis-related disorder, such as metastasis.


The subject may be at risk due to exposure to carcinogenic agents, being genetically predisposed to have the angiogenesis, and the like. Besides being useful for human treatment, these compounds
5 are also useful for veterinary treatment of mammals, including companion animals and farm animals, such as, but not limited to, horses, dogs, cats, cows, sheep and pigs. Preferably, subject means a human.

10

Inhibitors of the cyclooxygenase pathway in the metabolism of arachidonic acid used in the prevention and treatment of angiogenesis may inhibit enzyme activity through a variety of
15 mechanisms. By the way of example, the inhibitors used in the methods described herein may block the enzyme activity directly by acting as a substrate for the enzyme. The use of cyclooxygenase-2 selective inhibitors is highly
20 advantageous in that it minimize the gastric side effects that can occur with non-selective NSAID's, especially where prolonged prophylactic treatment is expected.

25 The term "cyclooxygenase-2 inhibitor" denotes a compound able to inhibit cyclooxygenase-2 without significant inhibition of cyclooxygenase-1. Preferably, it includes compounds which have a cyclooxygenase-2 IC_{50} of
30 less than about 0.2 μM , and also have a selectivity ratio of cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase-1
35 IC_{50} of greater than about 1 μM , and more preferably of greater than 10 μM .

The method provided herein relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in the prevention and treatment of angiogenesis. In the preferred embodiments, the cyclooxygenase-2 inhibitor is selected from compounds of Formula I



10

wherein A is a substituent selected from oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, cyclopentenyl, phenyl and pyridyl;

15 wherein R¹ is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R² is methyl or amino; and

25 wherein R³ is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxyaralkoxyalkyl, aminocarbonyl,

35

aminocarbonylalkyl, alkylaminocarbonyl, N-
arylamino carbonyl, N-alkyl-N-arylamino carbonyl,
alkylaminocarbonylalkyl, carboxyalkyl, alkylamino,
N-arylamino, N-aralkylamino, N-alkyl-N-
5 aralkylamino, N-alkyl-N-arylamino, aminoalkyl,
alkylaminoalkyl, N-arylaminoalkyl, N-
aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-
alkyl-N-arylaminoalkyl, aryloxy, aralkoxy,
arylthio, aralkylthio, alkylsulfinyl,
10 alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl,
N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-
arylaminosulfonyl; or a pharmaceutically-
acceptable salt thereof.

15 A preferred class of compounds which inhibit
cyclooxygenase-2 consists of compounds of Formula I
wherein A is selected from oxazolyl, isoxazolyl,
pyrazolyl, imidazolyl, cyclopentenyl, phenyl, and
pyridyl; wherein R¹ is selected from 5- and 6-
20 membered heterocyclyl, lower cycloalkyl, lower
cycloalkenyl and aryl selected from phenyl,
biphenyl and naphthyl, wherein R¹ is optionally
substituted at a substitutable position with one or
more radicals selected from lower alkyl, lower
25 haloalkyl, cyano, carboxyl, lower alkoxycarbonyl,
hydroxyl, lower hydroxyalkyl, lower haloalkoxy,
amino, lower alkylamino, phenylamino, lower
alkoxyalkyl, lower alkylsulfinyl, halo, lower
alkoxy and lower alkylthio; wherein R² is methyl or
30 amino; and wherein R³ is a radical selected from
hydrido, oxo, cyano, carboxyl, lower
alkoxycarbonyl, lower carboxyalkyl, lower
cyanoalkyl, halo, lower alkyl, lower alkyloxy,
lower cycloalkyl, phenyl, lower haloalkyl, 5- or 6-
35 membered heterocyclyl, lower hydroxylalkyl, lower
aralkyl, acyl, phenylcarbonyl, lower alkoxyalkyl,
5- or 6-membered heteroaryloxy, aminocarbonyl,

lower alkylaminocarbonyl, lower alkylamino, lower aminoalkyl, lower alkylaminoalkyl, phenyloxy, and lower aralkoxy; or a pharmaceutically-acceptable salt thereof.

5

A more preferred class of compounds which inhibit cyclooxygenase-2 consists of compounds of Formula I wherein A is selected from oxazolyl, isoxazolyl, pyrazolyl, imidazolyl and
10 cyclopentenyl; wherein R¹ is selected from pyridyl optionally substituted at a substitutable position with one or more methyl radicals, and phenyl optionally substituted at a substitutable position with one or more radicals selected from methyl,
15 ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, hydroxyl, hydroxymethyl, trifluoromethoxy, amino, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-N-ethylamino, phenylamino, methoxymethyl, methylsulfinyl, fluoro, chloro,
20 bromo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, and methylthio; wherein R² is methyl or amino; and wherein R³ is a radical selected from hydrido, oxo,
25 cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, carboxypropyl, carboxymethyl, carboxyethyl, cyanomethyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl,
30 hexyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, difluoroethyl, difluoropropyl, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, cyclohexyl, phenyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, pyrazinyl,
35 hydroxymethyl, hydroxylpropyl, benzyl, formyl, phenylcarbonyl, methoxymethyl, furylmethyloxy, aminocarbonyl, N-methylaminocarbonyl, N,N-

dimethylaminocarbonyl, N,N-dimethylamino, N-ethylamino, N,N-dipropylamino, N-butylamino, N-methyl-N-ethylamino, aminomethyl, N,N-dimethylaminomethyl, N-methyl-N-ethylaminomethyl,
5 benzyloxy, and phenyloxy; or a pharmaceutically-acceptable salt thereof.

A family of specific compounds of particular interest within Formula I consists of compounds
10 and pharmaceutically-acceptable salts thereof as follows:

5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole;
15 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole;
4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
20 4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-yl)benzenesulfonamide;
4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
25 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide;
30 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
35 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

- 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
5 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
10 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
15 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
20 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
25 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
30 2-methyl-4-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
2-methyl-6-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
35 2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;

- 4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-methyl-1H-imidazole;
5 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-phenyl-1H-imidazole;
2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-1H-imidazole;
2-(3-fluoro-4-methoxyphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
10 imidazole;
1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-trifluoromethyl-1H-imidazole;
2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole;
15 trifluoromethyl-1H-imidazole;
4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole;
20 imidazole;
4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazole;
25 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole;
4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
30 1-yl]benzenesulfonamide;
4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
35 1-allyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;

- 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-
1H-pyrazol-3-yl]benzenesulfonamide;
N-phenyl-[4-(4-fluorophenyl)-3-[4-
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-
5 pyrazol-1-yl]acetamide;
ethyl [4-(4-fluorophenyl)-3-[4-
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-
pyrazol-1-yl]acetate;
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-
10 (2-phenylethyl)-1H-pyrazole;
4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-
(2-phenylethyl)-5-(trifluoromethyl)pyrazole;
1-ethyl-4-(4-fluorophenyl)-3-[4-
(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-
15 pyrazole;
5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-
trifluoromethyl-1H-imidazole;
4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-
(trifluoromethyl)-1H-imidazole;
20 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-
phenylisoxazole;
4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-difluoromethyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
25 4-[5-hydroxymethyl-3-phenylisoxazol-4-
yl]benzenesulfonamide;
4-[5-methyl-3-phenyl-isoxazol-4-
yl]benzenesulfonamide;
1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-
30 (methylsulfonyl)benzene;
1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene;
1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene;
35 1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene;

- 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 5 1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
- 1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 10 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
- 4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
- 15 4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide;
- 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 20 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide;
- 1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
- 25 4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
- 4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide;
- ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl-acetate;
- 30 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid;
- 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
- 35 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
- 4-(4-fluorophenyl)-2-methyl-5-[4-


(methylsulfonyl)phenyl]oxazole; and
4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl]benzenesulfonamide.

5 A family of specific compounds of more particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows:

- 10 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-
15 1H-pyrazol-1-yl]benzenesulfonamide;
3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1H-imidazol-2-yl]pyridine;
20 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide;
4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
25 [2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide;
4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide;
and
30 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl)-4-oxazolyl]benzenesulfonamide.

A subclass of cyclooxygenase-2 inhibitors is selected from compounds of Formula II

15



wherein R^4 is selected from hydrido, alkyl, haloalkyl, alkoxycarbonyl, cyano, cyanoalkyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, aminocarbonylalkyl, alkoxycarbonylcyanoalkenyl and hydroxyalkyl;

wherein R^5 is selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and

wherein R^6 is selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R^4 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino;

or a pharmaceutically-acceptable salt or derivative thereof.

A class of compounds of particular interest consists of those compounds of Formula II wherein R^4 is selected from lower haloalkyl; wherein R^5 is hydrido; and wherein R^6 is selected from phenyl optionally substituted at a substitutable position with one or more radicals selected from halo, lower alkyl and lower alkoxy; or a pharmaceutically-acceptable salt or derivative thereof.

A family of specific compounds of particular interest within Formula I consists of compounds, derivatives and pharmaceutically-acceptable salts thereof as follows:

- 5 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
10 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
15 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
20 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; and
25 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

30 A family of specific compounds of more particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts or derivatives thereof as follows:

- 35 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; and

4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

Derivatives are intended to encompass any compounds
5 which are structurally related to the cyclooxygenase-2
inhibitors or which possess the substantially equivalent
biologic activity. By way of example, such inhibitors
may include, but are not limited to, prodrugs thereof.
Such compounds can be formed in vivo, such as by
10 metabolic mechanisms.

The term "hydrido" denotes a single hydrogen
atom (H). This hydrido radical may be attached,
for example, to an oxygen atom to form a hydroxyl
15 radical or two hydrido radicals may be attached
to a carbon atom to form a methylene (-CH₂-)
radical. Where used, either alone or within
other terms such as "haloalkyl", "alkylsulfonyl",
"alkoxyalkyl" and "hydroxyalkyl", the term
20 "alkyl" embraces linear or branched radicals
having one to about twenty carbon atoms or,
preferably, one to about twelve carbon atoms.
More preferred alkyl radicals are "lower alkyl"
radicals having one to about ten carbon atoms.
25 Most preferred are lower alkyl radicals having
one to about six carbon atoms. Examples of such
radicals include methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-
butyl, pentyl, iso-amyl, hexyl and the like. The
30 term "alkenyl" embraces linear or branched
radicals having at least one carbon-carbon double
bond of two to about twenty carbon atoms or,
preferably, two to about twelve carbon atoms.
More preferred alkenyl radicals are "lower
35 alkenyl" radicals having two to about six carbon
atoms. Examples of alkenyl radicals include
ethenyl, propenyl, allyl, propenyl, butenyl and

4-methylbutenyl. The term "alkynyl" denotes linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like. The terms "alkenyl", "lower alkenyl", embrace radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. The term "cycloalkyl" embraces saturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkenyl" embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. More preferred cycloalkenyl radicals are "lower cycloalkenyl" radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo

radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and "alkyloxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term "alkoxyalkyl" embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy. The term "aryl",

alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term

5 "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl,

10 alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxy carbonylalkyl, aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxy carbonyl and aralkoxy carbonyl. The term

15 "heterocyclyl" embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals

20 include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen

25 atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially

30 unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. The term "heteroaryl" embraces unsaturated heterocyclyl radicals. Examples of unsaturated heterocyclyl radicals, also termed

35 "heteroaryl" radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl,

pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-
5 tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl,
10 tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic
15 group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-
20 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-
25 membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed
30 heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term also embraces radicals where heterocyclyl radicals are fused with aryl radicals. Examples
35 of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said "heterocyclyl group" may have 1 to 3 substituents

such as alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms
5 attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio,
10 propylthio, butylthio and hexylthio. The term "alkylthioalkyl" embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkyl
15 radicals are "lower alkylthioalkyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl. The term "alkylsulfinyl" embraces radicals containing a
20 linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent $-S(=O)-$ radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having alkyl radicals of one to six carbon atoms. Examples of
25 such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent
30 radicals $-SO_2-$. "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms.
35 Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may

be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denote $\text{NH}_2\text{O}_2\text{S}-$. The term "acyl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. Examples of such lower alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl. The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes $-(\text{C}=\text{O})-$. The term "aroyl" embraces aryl radicals with a carbonyl radical as defined above. Examples of aroyl include benzoyl, naphthoyl, and the like and the aryl in said aroyl may be additionally substituted. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes $-\text{CO}_2\text{H}$. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More preferred are "lower carboxyalkyl" which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are "lower alkoxycarbonyl" radicals with alkyl portions having 1 to 6 carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl

and hexyloxycarbonyl. The terms "alkylcarbonyl", "arylcarbonyl" and "aralkylcarbonyl" include radicals having alkyl, aryl and aralkyl radicals, as defined above, attached to a carbonyl radical.

- 5 Examples of such radicals include substituted or unsubstituted methylcarbonyl, ethylcarbonyl, phenylcarbonyl and benzylcarbonyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
- 10 The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable. The term "heterocyclylalkyl" embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl and haloalkoxy. The term "aralkoxy" embraces aralkyl radicals attached through an oxygen atom
- 15 to other radicals. The term "aralkoxyalkyl" embraces aralkoxy radicals attached through an oxygen atom to an alkyl radical. The term "aralkylthio" embraces aralkyl radicals attached to a sulfur atom. The term "aralkylthioalkyl" embraces aralkylthio radicals attached through a sulfur atom to an alkyl radical. The term "aminoalkyl" embraces alkyl radicals substituted with one or more amino radicals. More preferred are "lower aminoalkyl" radicals. Examples of
- 20 such radicals include aminomethyl, aminoethyl, and the like. The term "alkylamino" denotes amino groups which have been substituted with one
- 25
- 30
- 35

or two alkyl radicals. Preferred are "lower N-alkylamino" radicals having alkyl portions having 1 to 6 carbon atoms. Suitable lower alkylamino may be mono or dialkylamino such as N-

5 methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like. The term "arylamino" denotes amino groups which have been substituted with one or two aryl radicals, such as N-phenylamino. The "arylamino" radicals may

10 be further substituted on the aryl ring portion of the radical. The term "aralkylamino" embraces aralkyl radicals attached through an amino nitrogen atom to other radicals. The terms "N-arylaminoalkyl" and "N-aryl-N-alkyl-aminoalkyl"

15 denote amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-

20 phenyl-N-methylaminomethyl. The term "aminocarbonyl" denotes an amide group of the formula $-C(=O)NH_2$. The term "alkylaminocarbonyl" denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the

25 amino nitrogen atom. Preferred are "N-alkylaminocarbonyl" "N,N-dialkylaminocarbonyl" radicals. More preferred are "lower N-alkylaminocarbonyl" "lower N,N-dialkylaminocarbonyl" radicals with lower alkyl

30 portions as defined above. The term "alkylaminoalkyl" embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical. The term "aryloxyalkyl" embraces radicals having an aryl radical attached to an

35 alkyl radical through a divalent oxygen atom. The term "arylthioalkyl" embraces radicals having an aryl radical attached to an alkyl radical

through a divalent sulfur atom.
The compounds utilized in the methods of the present invention may be present in the form of free bases or pharmaceutically acceptable acid addition salts thereof.

5 The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I

10 may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids

15 may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic,

20 anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic,

25 cyclohexylaminosulfonic, stearic, algenic, β -hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminum, calcium, lithium,


30 magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding

35 compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.

GENERAL SYNTHETIC PROCEDURES

The cyclooxygenase-2 inhibitor compounds of the invention can be synthesized according to the following procedures of Schemes I-X, wherein the R^1 - R^3 substituents are as defined for Formula I, above, except where further noted.

Scheme I




Synthetic Scheme I shows the preparation of cyclooxygenase-2 inhibitor compounds, as described in U.S. patent No. 5,521,207 and WQ95/15316, which are incorporated by reference, embraced by Formula I. In step 1, ketone 1 is treated with a base, preferably NaOMe or NaH, and an ester, or ester

15

equivalent, to form the intermediate diketone **2** (in the enol form) which is used without further purification. In step 2, diketone **2** in an anhydrous protic solvent, such as absolute ethanol or acetic acid, is treated with the hydrochloride salt or the free base of a substituted hydrazine at reflux to afford a mixture of pyrazoles **3** and **4**. Recrystallization or chromatography affords **3** usually as a solid. Similar pyrazoles can be prepared by methods described in U.S. Pat. Nos. 4,146,721, 5,051,518, 5,134,142 and 4,914,121 which also are incorporated by reference.

Scheme II




Scheme II shows the four step procedure for forming cyclooxygenase-2 inhibitor pyrazoles **8** as described in U.S. patent No. 5,486,534 (where R^a is hydrido or alkyl) from ketones **5**. In step 1, ketone **5** is reacted with a base, such as lithium bis(trimethylsilyl)amide or lithium diisopropylamide (LDA) to form the anion. In step 2, the anion is reacted with an acetylating reagent to provide diketone **6**. In step 3, the reaction of

diketone 6 with hydrazine or a substituted hydrazine, gives pyrazole 7. In step 4, the pyrazole 7 is oxidized with an oxidizing reagent, such as Oxone® (potassium peroxymonosulfate), 3-chloroperbenzoic acid (MCPBA) or hydrogen peroxide, to give a mixture of the desired 3-(alkylsulfonyl)phenyl-pyrazole 8 and the 5-(alkylsulfonyl)phenyl-pyrazole isomer. The desired pyrazole 8, usually a white or pale yellow solid, is obtained in pure form either by chromatography or recrystallization.

Alternatively, diketone 6 can be formed from ketone 5 by treatment with a base, such as sodium hydride, in a solvent, such as dimethylformamide, and further reacting with a nitrile to form an aminoketone. Treatment of the aminoketone with acid forms the diketone 6. Similar pyrazoles can be prepared by methods described in U.S. Pat. No. 3,984,431 which is incorporated by reference.

Scheme III




5 Cyclooxygenase-2 inhibitor diaryl/heteroaryl
 thiophenes (where T is S, and R^b is alkyl) can be
 prepared by the methods described in U.S. Patent
 Nos. 4,427,693, 4,302,461, 4,381,311, 4,590,205,
 and 4,820,827, and PCT documents WO 95/00501 and
 10 WO94/15932, which are incorporated by reference.

Similar pyrroles (where T is N), furanones and furans (where T is O) can be prepared by methods described in PCT documents WO 95/00501 and WO94/15932, and in EP799,823.

5


Scheme IV



Cyclooxygenase-2 inhibitor diaryl/heteroaryl oxazoles can be prepared by the methods described in U.S. Patent Nos. 3,743,656, 3,644,499 and 3,647,858, and PCT documents WO 95/00501 and WO94/27980, which are incorporated by reference. Equivalent oxazole compounds can be prepared via

15 WO96/19463 and WO96/19462.


Scheme V



- 5 Cyclooxygenase-2 inhibitor diaryl/heteroaryl
isoxazoles can be prepared by the methods described
in United States No. 5,633,272, PCT documents
WO92/05162, and WO92/19604, and European
Publication EP 26928 which are incorporated by
10 reference. Sulfonamides 24 can be formed from the
hydrated isoxazole 23 in a two step procedure.
First, hydrated isoxazole 23 is treated at about 0
°C with two or three equivalents of chlorosulfonic
acid to form the corresponding sulfonyl chloride.
15 In step two, the sulfonyl chloride thus formed is
treated with concentrated ammonia to provide the

sulfonamide derivative 24.

Scheme VI



Scheme VI shows the three step preparation of the cyclooxygenase-2 inhibitor imidazoles **29** of the present invention. In step 1, the reaction of substituted nitriles (R^1CN) **25** with primary phenylamines **26** in the presence of alkylaluminum reagents such as trimethylaluminum, triethylaluminum, dimethylaluminum chloride, diethylaluminum chloride in the presence of inert solvents such as toluene, benzene, and xylene, gives amidines **27**. In step 2, the reaction of amidine **27** with 2-haloketones (where X is Br or Cl)


in the presence of bases, such as sodium bicarbonate, potassium carbonate, sodium carbonate, potassium bicarbonate or hindered tertiary amines such as *N,N'*-diisopropylethylamine, gives the 4,5-
5 dihydroimidazoles **28** (where R^b is alkyl). Some of the suitable solvents for this reaction are isopropanol, acetone and dimethylformamide. The reaction may be carried out at temperatures of about 20°C to about 90°C. In step 3, the 4,5-
10 dihydroimidazoles **28** may be dehydrated in the presence of an acid catalyst such as 4-toluenesulfonic acid or mineral acids to form the 1,2-disubstituted imidazoles **29** of the invention. Suitable solvents for this dehydration step are
15 e.g., toluene, xylene and benzene. Trifluoroacetic acid can be used as solvent and catalyst for this dehydration step.

In some cases (e.g., where R^3 = methyl or phenyl) the intermediate **28** may not be readily
20 isolable. The reaction, under the conditions described above, proceeds to give the targeted imidazoles directly.

Similarly, imidazoles can be prepared having the sulfonylphenyl moiety attached at position 2
25 and R^1 attached at the nitrogen atom at position 1.

Diaryl/heteroaryl imidazoles can be prepared by the methods described in U.S. Patent Nos. 4,822,805, U.S. application Serial No. 08/282,395 and PCT document WO 93/14082, which are
30 incorporated by reference.

Scheme VII



The subject imidazole cyclooxygenase-2 inhibitor compounds **36** of this invention may be synthesized according to the sequence outlined in Scheme VII. Aldehyde **30** may be converted to the protected cyanohydrin **31** by reaction with a trialkylsilyl cyanide, such as trimethylsilyl cyanide (TMSCN) in the presence of a catalyst such as zinc iodide (ZnI₂) or potassium cyanide (KCN).

Reaction of cyanohydrin **31** with a strong base followed by treatment with benzaldehyde **32** (where R^2 is alkyl) and using both acid and base treatments, in that order, on workup gives benzoin

5 **33**. Examples of strong bases suitable for this reaction are lithium diisopropylamide (LDA) and lithium hexamethyldisilazane. Benzoin **33** may be converted to benzil **34** by reaction with a suitable oxidizing agent, such as bismuth oxide or manganese

10 dioxide, or by a Swern oxidation using dimethyl sulfoxide (DMSO) and trifluoroacetic anhydride. Benzil **34** may be obtained directly by reaction of the anion of cyanohydrin **31** with a substituted benzoic acid halide. Any of compounds **33** and **34**

15 may be used as intermediates for conversion to imidazoles **35** (where R^2 is alkyl) according to chemical procedures known by those skilled in the art and described by M. R. Grimmett, "Advances in Imidazole Chemistry" in **Advances in Heterocyclic**

20 **Chemistry**, **12**, 104 (1970). The conversion of **34** to imidazoles **35** is carried out by reaction with ammonium acetate and an appropriate aldehyde (R^3CHO) in acetic acid. Benzoin **36** may be converted to imidazoles **38** by reaction with


25 formamide. In addition, benzoin **36** may be converted to imidazoles by first acylating with an appropriate acyl group (R^3CO-) and then treating with ammonium hydroxide. Those skilled in the art will recognize that the oxidation of the sulfide

30 (where R^2 is methyl) to the sulfone may be carried out at any point along the way beginning with compounds **35**, and including oxidation of imidazoles **38**, using, for examples, reagents such as hydrogen peroxide in acetic acid, *m*-chloroperoxybenzoic acid

35 (MCPBA) and potassium peroxymonosulfate (OXONE®).

Diaryl/heteroaryl imidazoles can be prepared by the methods described in U.S. Patent Nos. 3,707,475, 4,686,231, 4,503,065, 4,472,422, 4,372,964, 4,576,958, 3,901,908, U.S. application 5 Serial No. 08/281,903 European publication EP 372,445, and PCT document WO 95/00501, which are incorporated by reference.


Scheme VIII



Diaryl/heteroaryl cyclopentene cyclooxygenase-


5 2 inhibitors can be prepared by the methods described in U.S. Patent No. 5,344,991, and PCT document WO 95/00501, which are incorporated by reference.

Scheme IX



Similarly, Synthetic Scheme IX shows the
5 procedure for the preparation of 1,2-diarylbenzene
cyclooxygenase-2 inhibitor agents **44** from 2-bromo-
biphenyl intermediates **43** (prepared similar to that
described in Synthetic Scheme VIII) and the
appropriate substituted phenylboronic acids. Using
10 a coupling procedure similar to the one developed
by Suzuki et al. [*Synth. Commun.*, **11**, 513 (1981)],
intermediates **43** are reacted with the boronic acids
in toluene/ethanol at reflux in the presence of a
 Pd^0 catalyst, e.g.,
15 tetrakis(triphenylphosphine)palladium(0), and 2M
sodium carbonate to give the corresponding 1,2-
diarylbenzene antiinflammatory agents **44** of this
invention. Such terphenyl compounds can be
prepared by the methods described in PCT patent
20 document WO96/16934, which is incorporated by
reference.

Scheme X



5

Diaryl/heteroaryl thiazole cyclooxygenase-2 inhibitors can be prepared by the methods described in U.S. Patent No. 4,051,250, 4,632,930, European Application EP 592,664, and PCT documents WO96/03392 and WO 95/00501, which are incorporated by reference. Isothiazoles can be prepared as described in PCT document WO 95/00501.

Diaryl/heteroaryl pyridine cyclooxygenase-2 inhibitors can be prepared by the methods described in U.S. Patent Nos. 5,169,857, 4,011,328, 4,533,666, and WO96/24584 and WO96/24585, which are incorporated by reference.

20

Biological Evaluation

25

Antiangiogenic Assay

To determine the effects of COX-2 inhibitors on angiogenesis in vivo, we tested selective compounds in the mouse and rat corneal micropocket assay. The mouse

30

corneal neovascularization micropocket model was performed with materials, reagents and procedures essentially as described by Muthukkaupah et al., *J. Natl. Cancer Inst.*, **69**, 699-708 (1982). In this assay, a pellet containing basic fibroblast growth factor (FGF) was implanted into the corneal stroma of the mouse and the newly formed vessels were measured using a slit lamp. In this model, COX-2 is expressed in the endothelial cells of the newly developed blood vessels. A COX-2 inhibitor, 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide inhibited FGF-induced angiogenesis in the mouse (70-90%) at a dose of 6 mg/kg/day.

In the rat micropocket assay, 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide given only once inhibited FGF-induced angiogenesis (~90%).

We also determined the effects of a COX-2 inhibitor (4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) in the mouse cornea using another angiogenic stimuli, vascular endothelial growth factor (VEGF). In this model, angiogenesis was inhibited (~50%) when the compound was given at a dose of 6 mg/kg.

Metastasis Model

A Murine Lewis lung carcinoma assay is performed as described by I. Anderson et al [*Can. Res.*, **56**, 715 (1996)]. A COX-2 inhibitor is effective in inhibiting metastasis in this model.

The present invention comprises a pharmaceutical

composition for the treatment of angiogenic disorders, comprising a therapeutically-effective amount of a compound of Formula I in association with at least one pharmaceutically-acceptable carrier, adjuvant or
5 diluent (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route known to those skilled in the art, preferably in the form of a
10 pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intra-vascularly, intraperitoneally, intranasal, intrabronchial,
15 subcutaneously, intramuscularly or topically (including aerosol). If the angiogenesis is localized, local administration rather than system administration is preferred. Formulation in a lipid vehicle may be used to enhance bioavailability.

20

The administration of the present invention may be for either prevention or treatment purposes. The methods and compositions used herein may be used alone or in conjunction with additional therapies known to those
25 skilled in the art in the prevention or treatment of angiogenesis. Alternatively, the methods and compositions described herein may be used as adjunct therapy. By way of example, the cyclooxygenase-2 inhibitor may be administered alone or in conjunction with other
30 antineoplastic agents or other growth inhibiting agents or other drugs or nutrients.

There are large numbers of antineoplastic agents available in commercial use, in clinical evaluation and
35 in pre-clinical development, which could be selected for treatment of angiogenesis by combination drug chemotherapy. Such antineoplastic agents fall into

several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.

- 5 Alternatively, other anti-neoplastic agents, such as metallomatrix proteases inhibitors (MMP), such as MMP-13 inhibitors including batistat, marimastat, Agouron Pharmaceuticals AG-3340, and Roche RO-32-3555, or $\alpha\beta$, inhibitors may be used.

10

- A first family of antineoplastic agents which may be used in combination with a selective cyclooxygenase-2 inhibitor consists of antimetabolite-type antineoplastic agents. Suitable antimetabolite antineoplastic agents may be selected from the group consisting of 5-FU-fibrinogen, acanthifolic acid, aminothiadiaazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015, fazarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N-(2'-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, tyrosine protein kinase inhibitors, Taiho UFT and uricytin.

- A second family of antineoplastic agents which may be used in combination with a selective cyclooxygenase-2 inhibitor consists of alkylating-type antineoplastic

agents. Suitable alkylating-type antineoplastic agents may be selected from the group consisting of Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, 5 budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto DACHP(Myrr)2, diphenylspiromustine, diplatinum 10 cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine phosphate sodium, fotemustine, Unimed G-6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine, mafosfamide, mitolactol, Nippon 15 Kayaku NK-121, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine, SmithKline SK&F-101772, Yakult Honsha SN-22, spiromustine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, 20 tetraplatin and trimelamol.

A third family of antineoplastic agents which may be used in combination with a selective cyclooxygenase-2 inhibitor consists of antibiotic-type antineoplastic 25 agents. Suitable antibiotic-type antineoplastic agents may be selected from the group consisting of Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, 30 anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, caliche mycin, 35 chromoximycin, dactinomycin, daunorubicin, Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC-88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B, ditrisarubicin B,

Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen,
elsamycin-A, epirubicin, erbstatin, esorubicin,
esperamicin-A1, esperamicin-Alb, Erbamont FCE-21954,
Fujisawa FK-973, fostriecin, Fujisawa FR-900482,
5 glidobactin, gregatin-A, grincamycin, herbimycin,
idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa
Hakko KM-5539, Kirin Brewery KRN-8602, Kyowa Hakko KT-
5432, Kyowa Hakko KT-5594, Kyowa Hakko KT-6149,
American Cyanamid LL-D49194, Meiji Seika ME 2303,
10 menogaril, mitomycin, mitoxantrone, SmithKline M-TAG,
neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT-01,
SRI International NSC-357704, oxalysine, oxaunomycin,
peplomycin, pilatin, pirarubicin, porothramycin,
pyrindamycin A, Tobishi RA-I, rapamycin, rhizoxin,
15 rodorubicin, sibanomycin, siwenmycin, Sumitomo SM-5887,
Snow Brand SN-706, Snow Brand SN-07, sorangicin-A,
sparsomycin, SS Pharmaceutical SS-21020, SS
Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B,
steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN-
20 868A, terpentecin, thrazine, tricrozarin A, Upjohn U-
73975, Kyowa Hakko UCN-10028A, Fujisawa WF-3405,
Yoshitomi Y-25024 and zorubicin.

A fourth family of antineoplastic agents which may
25 be used in combination with the selective
cyclooxygenase-2 inhibitor consists of a miscellaneous
family of antineoplastic agents selected from the group
consisting of alpha-carotene, alpha-difluoromethyl-
arginine, acitretin, Biotec AD-5, Kyorin AHC-52,
30 alstonine, amonafide, amphetinile, amsacrine,
Angiostat, ankinomycin, anti-neoplaston A10,
antineoplaston A2, antineoplaston A3, antineoplaston
A5, antineoplaston AS2-1, Henkel APD, aphidicolin
glycinate, asparaginase, Avarol, baccharin, batracylin,
35 benfluron, benzotript, Ipsen-Beaufour BIM-23015,
bisantrene, Bristo-Myers BMY-40481, Vestar boron-10,
bromofosfamide, Wellcome BW-502, Wellcome BW-773,

- caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner-Lambert CI-937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur,
- 5 claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Yakult Honsha CPT-11, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleate, dacarbazine, datelliptinium, didemnin-B, dihaematoporphyrin ether, dihydrolenperone, dinaline,
- 10 distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, elliprabin, elliptinium acetate, Tsumura EPMTC, ergotamine, etoposide, etretinate, fenretinide, Fujisawa FR-57704, gallium nitrate, genkwadaphnin, Chugai GLA-43, Glaxo GR-63178,
- 15 grifolan NMF-5N, hexadecylphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, isoglutamine, isotretinoin, Otsuka JI-36, Ramot K-477, Otsuak K-76COONa, Kureha Chemical K-AM, MECT Corp KI-8110, American Cyanamid L-623,
- 20 leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-186641, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, merbarone, merocyanine derivatives, methylanilinoacridine, Molecular Genetics MGI-136, minactivin, mitonafide, mitoquidone, mopidamol,
- 25 motretinide, Zenyaku Kogyo MST-16, N-(retinoyl)amino acids, Nisshin Flour Milling N-021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC-604782, NCI NSC-95580, octreotide,
- 30 Ono ONO-112, oquizanocine, Akzo Org-10172, pancratistatin, pazelliptine, Warner-Lambert PD-111707, Warner-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin,
- 35 probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-

Poulenc RP-49532, Rhone-Poulenc RP-56976, SmithKline
SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm
SP-10094, spatol, spirocyclopropane derivatives,
spirogermanium, Unimed, SS Pharmaceutical SS-554,
5 strypoldinone, Stypoldione, Suntory SUN 0237, Suntory
SUN 2071, superoxide dismutase, Toyama T-506, Toyama T-
680, taxol, Teijin TEI-0303, teniposide, thaliblastine,
Eastman Kodak TJB-29, tocotrienol, Topostin, Teijin TT-
82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain,
10 Eastman Kodak USB-006, vinblastine sulfate,
vincristine, vindesine, vinestramide, vinorelbine,
vintriptyl, vinzolidine, withanolides and Yamanouchi
YM-534.

15 Examples of radioprotective agents which may be
used in the combination chemotherapy of this invention
are AD-5, adchnon, amifostine analogues, detox,
dimesna, 1-102, MM-159, N-acylated-dehydroalanines,
TGF- Genentech, tiprotimod, amifostine, WR-151327, FUT-
20 187, ketoprofen transdermal, nabumetone, superoxide
dismutase (Chiron) and superoxide dismutase Enzon.

Methods for preparation of the antineoplastic
agents described above may be found in the literature.
25 Methods for preparation of doxorubicin, for example,
are described in U.S. Patents No. 3,590,028 and No.
4,012,448. Methods for preparing metallomatrix
protease inhibitors are described in EP 780386,
WO97/20824, WO96/15096. Methods for preparing SOD
30 mimics are described in EP 524,101. Methods for
preparing $\alpha\beta$, inhibitors are described in WO97/08174.

In addition, the selective COX-2 inhibitor may be
administered in conjunction with other antiinflammatory
35 agents for maximum safety and efficacy, including
NSAID's, selective COX-1 inhibitors and inhibitors of

the leukotriene pathway, including 5-lipoxygenase inhibitors. Examples of NSAID's include indomethacin, naproxen, ibuprofen, salicylic acid derivatives such as aspirin, diclofenac, ketorolac, piroxicam, meloxicam, mefenamic acid, sulindac, tolmetin sodium, zomepirac, fenoprofen, phenylbutazone, oxyphenbutazone, nimesulide, zaltoprofen and etodolac.

The phrase "adjunct therapy" (or "combination therapy"), in defining use of a cyclooxygenase-2 inhibitor agent and one or more other pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single formulation having a fixed ratio of these active agents, or in multiple, separate formulations for each agent.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate.. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

For intravenous, intramuscular, subcutaneous, or intraperitoneal administration, the compound may be combined with a sterile aqueous solution which is preferably isotonic with the blood of the recipient. Such formulations may be prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride, glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. The formulations may be present in unit or multi-dose containers such as sealed ampoules or vials.

If the angiogenesis is localized in the G.I. tract, the compound may be formulated with acid-stable, base-labile coatings known in the art which begin to dissolve in the high pH small intestine. Formulation to enhance local pharmacologic effects and reduce systemic uptake are preferred.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably made isotonic. Preparations for injections may also be formulated by suspending or emulsifying the compounds in non-aqueous solvent, such as vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol.

Formulations for topical use include known gels, creams, oils, and the like. For aerosol delivery, the compounds may be formulated with known aerosol excipients, such as saline, and administered using commercially available nebulizers. Formulation in a fatty acid source may be used to enhance biocompatibility. Aerosol delivery is the preferred

method of delivery for epithelial angiogenesis of the lung for prevention application.

For rectal administration, the active ingredient may
5 be formulated into suppositories using bases which are solid at room temperature and melt or dissolve at body temperature. Commonly used bases include coca butter, glycerinated gelatin, hydrogenated vegetable oil, polyethylene glycols of various molecular weights, and
10 fatty esters of polyethylene stearate.

The dosage form and amount can be readily established by reference to known treatment or prophylactic regimens. The amount of therapeutically
15 active compound that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of
20 the disease, the route and frequency of administration, and the particular compound employed, the location of the angiogenesis, as well as the pharmacokinetic properties of the individual treated, and thus may vary widely. The dosage will generally be lower if the
25 compounds are administered locally rather than systemically, and for prevention rather than for treatment. Such treatments may be administered as often as necessary and for the period of time judged necessary by the treating physician. One of skill in
30 the art will appreciate that the dosage regime or therapeutically effective amount of the inhibitor to be administered may need to be optimized for each individual. The pharmaceutical compositions may contain active ingredient in the range of about 0.1 to 2000 mg, preferably in the range of about 0.5 to 500 mg and most
35 preferably between about 1 and 200 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between


about 0.1 and about 50 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.

- 5 All documents referenced herein are incorporated by reference.

10 Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

What is claimed is:

1. A method for treating or preventing an angiogenesis-related disorder in a subject in need of such treatment or prevention, the method comprises treating the subject with a therapeutically effective amount of a cyclooxygenase-2 inhibitor of Formula I



10

wherein A is a substituent selected from oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, cyclopentenyl, phenyl and pyridyl;

- 15 wherein R¹ is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R¹ is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxy, carbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfonyl, halo, alkoxy and alkylthio;

wherein R² is methyl or amino; and

- 25 wherein R³ is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocycloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxy, carbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl,
- 30

- alkoxycarbonylalkyl, aminocarbonyl,
aminocarbonylalkyl, alkylaminocarbonyl, N-
arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl,
alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-
5 arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-
alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-
arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-
aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy,
aralkoxy, arylthio, aralkylthio, alkylsulfinyl,
10 alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-
arylaminosulfonyl, arylsulfonyl, N-alkyl-N-
arylaminosulfonyl; or a pharmaceutically-acceptable
salt thereof.
- 15 2. The method of Claim 1 wherein the angiogenesis-
related disorder is selected from metastasis, ocular
neovascularization, retinal neovascularization, diabetic
retinopathy, infantile hemangiomas, and disorders of the
female reproductive system.
- 20 3. The method of Claim 2 wherein the angiogenesis-
related disorder is endometriosis.
4. The method of Claim 2 wherein the angiogenesis-
25 related disorder is diabetic retinopathy.
5. The method of Claim 4 wherein A is selected
from oxazolyl, isoxazolyl, pyrazolyl, imidazolyl,
cyclopentenyl, phenyl, and pyridyl; wherein R¹ is
30 selected from 5- and 6-membered heterocyclyl, lower
cycloalkyl, lower cycloalkenyl and aryl selected from
phenyl, biphenyl and naphthyl, wherein R¹ is
optionally substituted at a substitutable position
with one or more radicals selected from lower alkyl,

lower haloalkyl, cyano, carboxyl, lower
alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower
haloalkoxy, amino, lower alkylamino, phenylamino,
lower alkoxyalkyl, lower alkylsulfinyl, halo, lower
5 alkoxy and lower alkylthio; wherein R^2 is methyl or
amino; and wherein R^3 is a radical selected from
hydrido, oxo, cyano, carboxyl, lower alkoxyalkyl,
lower carboxyalkyl, lower cyanoalkyl, halo, lower
alkyl, lower alkyloxy, lower cycloalkyl, phenyl,
10 lower haloalkyl, 5- or 6-membered heterocyclyl, lower
hydroxylalkyl, lower aralkyl, acyl, phenylcarbonyl,
lower alkoxyalkyl, 5- or 6-membered heteroaryloxy,
aminocarbonyl, lower alkylaminocarbonyl, lower
alkylamino, lower aminoalkyl, lower alkylaminoalkyl,
15 phenyloxy, and lower aralkoxy; or a pharmaceutically-
acceptable salt thereof.

6. The method of Claim 5 wherein A is selected from
oxazolyl, isoxazolyl, pyrazolyl, imidazolyl and
20 cyclopentenyl; wherein R^1 is selected from pyridyl
optionally substituted at a substitutable position
with one or more methyl radicals, and phenyl
optionally substituted at a substitutable position
with one or more radicals selected from methyl,
25 ethyl, isopropyl, butyl, tert-butyl, isobutyl,
pentyl, hexyl, fluoromethyl, difluoromethyl,
trifluoromethyl, cyano, carboxyl, methoxycarbonyl,
ethoxycarbonyl, hydroxyl, hydroxymethyl,
trifluoromethoxy, amino, N-methylamino, N,N-
30 dimethylamino, N-ethylamino, N,N-dipropylamino, N-
butylamino, N-methyl-N-ethylamino, phenylamino,
methoxymethyl, methylsulfinyl, fluoro, chloro, bromo,
methoxy, ethoxy, propoxy, n-butoxy, pentoxy, and
methylthio; wherein R^2 is methyl or amino; and
35 wherein R^3 is a radical selected from hydrido, oxo,
cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl,

carboxypropyl, carboxymethyl, carboxyethyl,
cyanomethyl, fluoro, chloro, bromo, methyl, ethyl,
isopropyl, butyl, tert-butyl, isobutyl, pentyl,
hexyl, difluoromethyl, trifluoromethyl,
5 pentafluoroethyl, heptafluoropropyl, difluoroethyl,
difluoropropyl, methoxy, ethoxy, propoxy, n-butoxy,
pentoxy, cyclohexyl, phenyl, pyridyl, thienyl,
thiazolyl, oxazolyl, furyl, pyrazinyl,
hydroxymethyl, hydroxylpropyl, benzyl, formyl,
10 phenylcarbonyl, methoxymethyl, furylmethyloxy,
aminocarbonyl, N-methylaminocarbonyl, N,N-
dimethylaminocarbonyl, N,N-dimethylamino, N-
ethylamino, N,N-dipropylamino, N-butylamino, N-
methyl-N-ethylamino, aminomethyl, N,N-
15 dimethylaminomethyl, N-methyl-N-ethylaminomethyl,
benzyloxy, and phenyloxy; or a pharmaceutically-
acceptable salt thereof.

7. The method of Claim 6 wherein the compound is
20 selected from compounds, and their pharmaceutically
acceptable salts, of the group consisting of

5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-
(trifluoromethyl)pyrazole;
25 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-
phenyl-3-(trifluoromethyl)pyrazole;
4-(5-(4-chlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-
yl)benzenesulfonamide
4-(3,5-bis(4-methylphenyl)-1H-pyrazol-1-
30 yl)benzenesulfonamide;
4-(5-(4-chlorophenyl)-3-phenyl-1H-pyrazol-1-
yl)benzenesulfonamide;
4-(3,5-bis(4-methoxyphenyl)-1H-pyrazol-1-
yl)benzenesulfonamide;
35 4-(5-(4-chlorophenyl)-3-(4-methylphenyl)-1H-pyrazol-1-
yl)benzenesulfonamide;

- 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide;
- 5 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide
- 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 10 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 15 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 20 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
- 25 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[3-cyano-5-(4-fluorophenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 30 4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
- 4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
- 35 4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

- 4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-
1H-pyrazol-1-yl]benzenesulfonamide;
2-methyl-4-[1-[4-(methylsulfonyl)phenyl]-4-
(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
5 2-methyl-6-[1-[4-(methylsulfonyl)phenyl]-4-
(trifluoromethyl)-1H-imidazol-2-yl]pyridine;
4-[2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-
imidazol-1-yl]benzenesulfonamide;
2-(3,4-difluorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-
10 (trifluoromethyl)-1H-imidazole;
4-[2-(4-methylphenyl)-4-(trifluoromethyl)-1H-imidazol-
1-yl]benzenesulfonamide;
2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-
methyl-1H-imidazole;
15 2-(4-chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-4-
phenyl-1H-imidazole;
2-(4-chlorophenyl)-4-(4-fluorophenyl)-1-[4-
(methylsulfonyl)phenyl]-1H-imidazole;
2-(3-fluoro-4-methoxyphenyl)-1-[4-
20 (methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-
imidazole;
1-[4-(methylsulfonyl)phenyl]-2-phenyl-4-
trifluoromethyl-1H-imidazole;
2-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-
25 trifluoromethyl-1H-imidazole;
4-[2-(3-chloro-4-methylphenyl)-4-(trifluoromethyl)-1H-
imidazol-1-yl]benzenesulfonamide;
2-(3-fluoro-5-methylphenyl)-1-[4-
(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-
30 imidazole;
4-[2-(3-fluoro-5-methylphenyl)-4-(trifluoromethyl)-1H-
imidazol-1-yl]benzenesulfonamide;
2-(3-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-
trifluoromethyl-1H-imidazole;
35 4-[2-(3-methylphenyl)-4-trifluoromethyl-1H-imidazol-1-
yl]benzenesulfonamide;

- 1-[4-(methylsulfonyl)phenyl]-2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazole;
- 4-[2-(3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 5 4-[2-phenyl-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 4-[2-(4-methoxy-3-chlorophenyl)-4-trifluoromethyl-1H-imidazol-1-yl]benzenesulfonamide;
- 1-allyl-4-(4-fluorophenyl)-3-[4-
- 10 (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole;
- 4-[1-ethyl-4-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]benzenesulfonamide;
- N-phenyl-[4-(4-fluorophenyl)-3-[4-
- 15 (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetamide;
- ethyl [4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetate;
- 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-
- 20 phenylethyl)-1H-pyrazole;
- 4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-1-(2-phenylethyl)-5-(trifluoromethyl)pyrazole;
- 1-ethyl-4-(4-fluorophenyl)-3-[4-
- (methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-
- 25 pyrazole;
- 5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-2-trifluoromethyl-1H-imidazole;
- 4-[4-(methylsulfonyl)phenyl]-5-(2-thiophenyl)-2-(trifluoromethyl)-1H-imidazole;
- 30 5-difluoromethyl-4-(4-methylsulfonylphenyl)-3-phenylisoxazole;
- 4-[3-ethyl-5-phenylisoxazol-4-yl]benzenesulfonamide;
- 4-[5-difluoromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;
- 35 4-[5-hydroxymethyl-3-phenylisoxazol-4-yl]benzenesulfonamide;


- 4-[5-methyl-3-phenyl-isoxazol-4-yl]benzenesulfonamide;
1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
1-[2-(4-fluoro-2-methylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
5 1-[2-(4-chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
1-[2-(2,4-dichlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
10 1-[2-(4-trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
1-[2-(4-methylthiophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
1-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
15 4-[2-(4-fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
1-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-(methylsulfonyl)benzene;
20 4-[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide;
4-[2-(4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
4-[2-(4-chlorophenyl)cyclopenten-1-yl]benzenesulfonamide;
25 1-[2-(4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
1-[2-(2,3-difluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
30 4-[2-(3-fluoro-4-methoxyphenyl)cyclopenten-1-yl]benzenesulfonamide;
1-[2-(3-chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene;
4-[2-(3-chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide;
35

4-[2-(2-methylpyridin-5-yl)cyclopenten-1-yl]benzenesulfonamide;
 ethyl 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]-2-benzyl-acetate;
 5 2-[4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazol-2-yl]acetic acid;
 2-(tert-butyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]oxazole;
 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-phenyloxazole;
 10 4-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]oxazole; and
 4-[5-(3-fluoro-4-methoxyphenyl)-2-trifluoromethyl-4-oxazolyl]benzenesulfonamide.

15

8. A method of treating an angiogenesis-related disorder in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula II

20



wherein R⁴ is selected from hydrido, alkyl, haloalkyl, alkoxy carbonyl, cyano, cyanoalkyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxy carbonylalkylaminocarbonyl, aminocarbonylalkyl, alkoxy carbonylcyanoalkenyl and hydroxyalkyl;

wherein R⁵ is selected from hydrido, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl and halo; and

wherein R⁶ is selected from aralkenyl, aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R⁴ is optionally substituted at a substitutable position with one or more radicals selected from halo, alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, hydroxyl, alkenyl, hydroxyalkyl, carboxyl, cycloalkyl, alkylamino, dialkylamino, alkoxycarbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic and amino; or a pharmaceutically-acceptable salt or derivative thereof.

9. The method of Claim 8 wherein R⁴ is selected from lower haloalkyl; wherein R⁵ is hydrido; and wherein R⁶ is selected from phenyl optionally substituted at a substitutable position with one or more radicals selected from halo, lower alkyl and lower alkoxy; or a pharmaceutically-acceptable salt or derivative thereof.

10. The method of Claim 9 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
5 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;
10 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; and
4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

15

11. The method of Claim 9 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

20 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; and
4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
25



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/415, 31/18, 31/42, 31/44, 31/10	A3	(11) International Publication Number: WO 98/22101 (43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21489 (22) International Filing Date: 19 November 1997 (19.11.97) (30) Priority Data: 60/031,404 19 November 1996 (19.11.96) US (71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MASFERRER, Jaime, L. [CL/US]; 1213 Blairshire, Ballwin, MO 63011 (US). RAZ, Amiram [IL/IL]; Tarad Street 9, Ramat-Gan, 52503 Israel (IL). (74) Agent: BULLOCK, Joseph, W.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 25 June 1998 (25.06.98)	
(54) Title: METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS (57) Abstract <p>This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating angiogenic disorders.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

 Internat: I Application No
 PCT/US 97/21489

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/415 A61K31/18 A61K31/42 A61K31/44 A61K31/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 96 36623 A (MERCK FROSST CANADA INC.) 21 November 1996 see claims 1,18,20,27,29 see page 20, line 19 - line 24 ---	1,2,4
Y	WO 95 15316 A (G. D. DEARLE & CO) 8 June 1995 cited in the application see claims 16-18,34-36,52-54 see page 7, line 8 - page 8, line 16 --- -/--	1,2,4-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

8 April 1998

Date of mailing of the international search report

15.05.98

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 97/21489

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL AN: 97000517, M. P. SEED: "Angiogenesis inhibition as a drug target for disease: An update" XP002061818 & Expert Opinion on Investigational Drugs, (1996) 5/12 (1617-1637) see abstract ---	1,2,4-11
Y	WO 96 06840 A (MERCK FROSST CANADA INC.) 7 March 1996 see claims 1-16,18-20,22 see page 9, line 21 - line 26 ---	1,2,4
Y	WO 94 15932 A (G. D. SEARLE & CO) 21 July 1994 cited in the application see claims 12-15,17-22 see page 2, line 24 - line 29 ---	1,2,4
A	DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL AN: 84204268, R. ROCHELS: "Tierexperimentelle Untersuchungen zur Rolle von Entzündungsmediatoren bei der Hornhautneovaskularisation" XP002061819 & Doc. Ophthalmol., 1984, 57/3, (215-262) see abstract ---	1-11
A	GB 2 283 745 A (MERCK FROSST CANADA INC.) 17 May 1995 see claims 1-7 see page 8, line 1 - line 5 ---	1,2,4
A	WO 96 19469 A (MERCK FROSST CANADA INC.) 27 June 1996 cited in the application see claims 1,2,21,23,25,27 see page 22, line 4 - line 16 -----	1,2,4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/21489

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 1-11

because they relate to subject matter not required to be searched by this Authority, namely:

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Remark : Although claims 1-11 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/US 97/21489

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9636623 A	21-11-96	US 5691374 A	25-11-97
		AU 5642496 A	29-11-96
		EP 0828724 A	18-03-98

WO 9515316 A	08-06-95	US 5466823 A	14-11-95
		US 5521207 A	28-05-96
		AU 1171495 A	19-06-95
		CA 2177576 A	08-06-95
		CN 1141630 A	29-01-97
		CZ 9601503 A	11-12-96
		EP 0731795 A	18-09-96
		FI 962249 A	29-05-96
		HU 74180 A	28-11-96
		JP 9506350 T	24-06-97
		NO 962184 A	29-05-96
		PL 314695 A	16-09-96
		US 5510496 A	23-04-96
		US 5563165 A	08-10-96
		US 5508426 A	16-04-96
		US 5516907 A	14-05-96
		US 5504215 A	02-04-96
		ZA 9409418 A	28-11-95

WO 9606840 A	07-03-96	US 5521213 A	28-05-96
		AU 3249295 A	22-03-96
		CA 2197895 A	07-03-96
		EP 0778834 A	18-06-97

WO 9415932 A	21-07-94	AT 160345 T	15-12-97
		AU 6027694 A	15-08-94
		CA 2152792 A	21-07-94
		DE 69406903 D	02-01-98
		EP 0679157 A	02-11-95
		EP 0759432 A	26-02-97
		EP 0764644 A	26-03-97
		EP 0764645 A	26-03-97
		JP 8510718 T	12-11-96

GB 2283745 A	17-05-95	US 5436265 A	25-07-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/21489

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9619469 A	27-06-96	AU 4294196 A	10-07-96
		CA 2206978 A	27-06-96
		EP 0799218 A	08-10-97
